nad+ and tirzepatide together with in script (combo) : r/tirzepatidecompound Tirzepatide ameliorates cisplatin-induced acute kidney

The duration of the therapeutic response varies widely: a day or up to weeks

Tirzepatide offers cardiovascular protection (38% reduction in heart failure events), liver fat reduction and MASH resolution (44-62% of patients), sleep apnea improvement (up to 63% AHI reduction), blood pressure reduction (up to 5.8 mmHg), cholesterol improvement (24.9% triglyceride reduction), kidney protection (33% fewer major kidney events), joint pain reduction, PCOS symptom improvement, and systemic inflammation reduction

The maximum licensed dose varies depending on the indication: up to 15 mg weekly for type 2 diabetes and up to 15 mg weekly for weight management in the UK

Consequently, the potential for unpublished studies with null or negative results to influence our findings cannot be ruled out